Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Sarcoma 2Genitourinary 2Dermatologic 2Thoracic 1Gastrointestinal 1

Conditions

Melanoma 2Skin Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
vitespin × Dermatologic × Clear all
NCT02452281 2016-01-25

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

The University of Texas Health Science Center, Houston

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT00039000 2012-09-07

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Agenus Inc.

Phase 3 Completed
350 enrolled
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡